Nimbus Therapeutics LLC:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nimbus Therapeutics LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10568
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nimbus Therapeutics LLC (Nimbus Therapeutics), formerly Nimbus Discovery LLC, is a biotechnology company that develops medicines for critical diseases such as metabolic disease, cancer, and immune-inflammatory disorders. The company harnesses its expertise in deep computational chemistry to offer a diverse pipeline of novel small molecule compounds such as IRAK4 inhibitors, Tyk2 (tyrosine kinase 2), STING antagonist, STING agonist, and acetyl-CoA carboxylase for the treatment of metabolic disease, inflammatory bowel diseases, SLE (lupus), rheumatoid arthritis, gout, Crohn’s disease, psoriasis and multiple sclerosis. Nimbus Therapeutics partners with academia and industry organizations for drug discovery and development. The company offers its products across the US. Nimbus Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Nimbus Therapeutics LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Nimbus Therapeutics Raises USD65 Million in Financing 10
Nimbus Therapeutics Raises USD43 Million in Series B Financing 12
Partnerships 14
Nimbus Therapeutics Enters into Agreement with Celgene 14
Nimbus Therapeutics Enters into Agreement with Charles River Laboratories International 15
Nimbus Discovery Enters Into Co-Development Agreement With Shire 16
Licensing Agreements 17
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 17
Acquisition 18
Gilead Sciences Acquires Nimbus Apollo from Nimbus Therapeutics 18
Nimbus Therapeutics LLC – Key Competitors 19
Nimbus Therapeutics LLC – Key Employees 20
Nimbus Therapeutics LLC – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Corporate Communications 22
Oct 04, 2018: Nimbus Therapeutics names Jeb Keiper as President and Chief Executive Officer 22
Jul 09, 2018: Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology 23
Mar 08, 2018: Nimbus Therapeutics Announces Departure of Chief Scientific Officer Rosana Kapeller, M.D., Ph.D. 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Key Facts 2
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nimbus Therapeutics LLC, Deals By Therapy Area, 2012 to YTD 2018 8
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Nimbus Therapeutics Raises USD65 Million in Financing 10
Nimbus Therapeutics Raises USD43 Million in Series B Financing 12
Nimbus Therapeutics Enters into Agreement with Celgene 14
Nimbus Therapeutics Enters into Agreement with Charles River Laboratories International 15
Nimbus Discovery Enters Into Co-Development Agreement With Shire 16
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 17
Gilead Sciences Acquires Nimbus Apollo from Nimbus Therapeutics 18
Nimbus Therapeutics LLC, Key Competitors 19
Nimbus Therapeutics LLC, Key Employees 20

List of Figures
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nimbus Therapeutics LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Nimbus Therapeutics LLC:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Alder Biopharmaceuticals Inc (ALDR):企業の財務・戦略的SWOT分析
    Alder Biopharmaceuticals Inc (ALDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • CMS Energy Corporation (CMS):電力:M&Aディール及び事業提携情報
    Summary CMS Energy Corporation (CMS Energy) is an energy utility which provides electricity, natural gas, and banking services. It generates, procures, transmits, distributes, and sells energy. The company produces power from coal, oil and gas, hydro, wind, and solar sources. CMS Energy purchases, t …
  • IMV Inc (IMV):企業の財務・戦略的SWOT分析
    Summary IMV Inc (IMV), formerly Immunovaccine Inc, is a biopharmaceutical company that develops immunotherapies and vaccines to treat cancer and infectious diseases. The company is investigating its pipeline candidates DPX-Survivac against ovarian, bladder, liver, non-small cell lung cancer and diff …
  • Hurtigruten AS:企業の戦略・SWOT・財務分析
    Hurtigruten AS - Strategy, SWOT and Corporate Finance Report Summary Hurtigruten AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Inception Sciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Inception Sciences Inc (Inception Sciences) is a pharmaceutical company that offers drug discovery incubators. The company develops new companies in partnership with academic researchers and biopharmaceutical companies. It develops drugs for various indications such as fibrotic diseases, onc …
  • Fluent Inc (FLNT):企業の財務・戦略的SWOT分析
    Fluent Inc (FLNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Pirelli & C. S.p.A.:企業の戦略・SWOT・財務情報
    Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Rizzani De Eccher S.P.A.
    Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Altern Energy Ltd (ALTN):企業の財務・戦略的SWOT分析
    Altern Energy Ltd (ALTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Banca Dello Stato Del Cantone Ticino
    Banca Dello Stato Del Cantone Ticino - Strategy, SWOT and Corporate Finance Report Summary Banca Dello Stato Del Cantone Ticino - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Lakewood-Amedex Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Lakewood-Amedex Inc (Lakewood-Amedex) is a clinical-stage pharmaceutical company with focus on the development of antimicrobial and antifungal medicines to address unmet needs in the treatment of serious infectious diseases. The company develops anti-infective products such as anti-bacterial …
  • Oxford Biodynamics Plc:企業の製品パイプライン分析2018
    Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neu …
  • Select Medical Holdings Corporation:企業の戦略・SWOT・財務情報
    Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Bonjour Holdings Limited:企業の戦略・SWOT・財務情報
    Bonjour Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Bonjour Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Intezyne Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Intezyne Inc (Intezyne) is a biotechnology company that develops product candidates for the treatment of various cancer tumors. The company offers anti-cancer agents and IVECT method to improve cancer therapy. It provides compounds that are cellular or molecularly targeted or have tumor-spec …
  • FLX Bio Inc-製薬・医療分野:企業M&A・提携分析
    Summary FLX Bio Inc (FLX Bio) focuses on the discovery, development and commercialization of novel immuno-oncology agents. The company’s pipeline product, FLX925 is a drug targeting the FLT3 mutations which is found in patients with acute myeloid leukemia (AML). FLX925 simultaneously targets a secon …
  • Vascular Biogenics Ltd (VBLT):企業の財務・戦略的SWOT分析
    Summary Vascular Biogenics Ltd (VBL) is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company’s product pipeline includes VB-111. VBL’s product VB-111 is an anti-angiogenic agent for the specific inhibition of tumor vascular growth for ca …
  • Sysmex Inostics GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Sysmex Inostics GmbH (Sysmex Inostics), formerly Inostics GmbH, a subsidiary of Sysmex Corp, is a molecular diagnostics company that offers blood-based cell-free tumor treatment solutions. The company offers services such as clinical trials, research and development, and testing for physicia …
  • Mangalam Drugs and Organics Ltd (MANGALAM):企業の財務・戦略的SWOT分析
    Summary Mangalam Drugs and Organics Ltd (MDOL) carries out manufacturing and supplying of specialty chemicals, intermediates, and active pharmaceutical ingredients. The company's active pharmaceutical ingredients include amodiaquine HCl, bisoprolol fumarate, artemether, dihydroartemisinin, hydroxy c …
  • Gem Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Gem Pharmaceuticals LLC (Gem Pharmaceuticals) is a clinical-stage biopharmaceutical company that develops proprietary anthracycline derivatives. The company’s pipeline products include GPX-150 for oncology, topical GPX-150 for inflammation, GPX 150 oral formulations and potency analogues pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆